The 30-Day Follow-Up Result of FIRE2-DIABETES

The 22nd GW-ICC was held at China National Convention Center in Beijing from October 10-16. During the congress, MicroPort organized a satellite meeting on the theme of Firebird2 drug-eluting stents in the treatment of complex lesions in diabetic patients. MicroPort also published the 30-day follow-up result of the FIRE2-DIABETES clinical studies. According to the result of the clinical studies, the success rate was 100% with 100% lesion achievement ratio, 0.3% 30-day cumulative cardiac death rate. The incidence of TVR, MACE and Late Thrombosis was 0.3%, 0.8% and 0.4% respectively. Meanwhile, the 6-month and 1-year follow-up of the clinical studies are also in process.
FIRE2-DIABETES is the first international multi-center prospective clinical registry research in China, using Cocr drug-eluting stents to treat complex coronary lesion in diabetic patients. All of the implanted stents were Firebird2 Cocr alloyed sirolimus-eluting stents. The findings of the research will provide scientific evidence in the treatment of complex coronary lesion in diabetic patients and further prove the efficacy and safety of Firebird2.